About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a publicly listed company based in San Rafael (United States) founded in 1997. Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. BioMarin Pharmaceutical has raised $37.5 million across 7 funding rounds from investors including Pfizer, Temasek and BB Biotech Ventures. The company has 3,040 employees. BioMarin Pharmaceutical has completed 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma and Kuvan. Its chief executive, as recorded, is Jean Jacques Bienaime. Its website biomarin.com draws about 150 thousand monthly visits. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Ultragenyx, Alnylam and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, United States. Therapeutics are developed by the company for rare genetic diseases within the biopharmaceutical sector. Multiple products have been created for conditions including mucopolysaccharidosis syndrome and phenylketonuria. Additional therapies are being advanced for disorders such as Duchenne muscular dystrophy, hemophilia A, and Pompe disease. Operations focus on research and product development for these specialized treatments.
- Headquarters San Rafael, United States
- Employees 3,040
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website biomarin.com
- Social LinkedIn X Facebook Instagram
- Legal Name Biomarin Pharmaceutical Inc.
- Annual Revenue$3.24 B (USD)14.18as on Dec 31, 2025
- Net Profit$348.9 M (USD)-18.26as on Dec 31, 2025
- EBITDA$971.86 M (USD)55.19as on Dec 31, 2025
- Total Equity Funding$37.5M (USD)
in 7 rounds
- Latest Funding Round$500M (USD), Post-IPO
May 2020
- InvestorsPfizer
& 3 more
- Employee Count3,040
- Investments & AcquisitionsAmicus Therapeutics
& 6 more
Funding Insights of BioMarin Pharmaceutical
BioMarin Pharmaceutical has successfully raised a total of $37.5M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.5M
- Total Rounds 7
- Last Round Post-IPO — $500M
- First Round $1.5M
(Feb 1997)
- Investors Count 4
All 7 funding rounds of BioMarin Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $500M | Post-IPO | – | – | – |
| Nov 2018 | $200M | Debt – Conventional | – | – | – |
| Jun 2018 | $20M | Post-IPO | – | – | |
| May 2014 | $106M | Post-IPO | – | – | |
| Apr 1999 | $26M | Series B | – | – | – |
| Jan 1998 | $10M | Series A | – | – | |
| Feb 1997 | $1.5M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in BioMarin Pharmaceutical
BioMarin Pharmaceutical has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Temasek and BB Biotech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
| bbbiotechventures.com | ||||
ROMA99 is recognized as a trusted online gaming platform. | grosvenorfund.com | |||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for BioMarin Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioMarin Pharmaceutical
763 people are tracked at BioMarin Pharmaceutical (336 in leadership, 10 in board & advisors, 417 in team); the tracked headcount is 3,040.
| Name | Role | Group |
|---|---|---|
Jean Jacques Bienaime | CEO & Chairman | Leadership |
Shana Whitehurst van Stralen | Head Of Global Supplier Quality | Leadership |
Lindsay Boyce | Director, RED PMO Group Lead, R&d PMO | Leadership |
Luke Ingram | Director, Fp&a - Skeletal Conditions BU | Leadership |
Travis Wilson | Associate Director, Engineering And Process Team Support | Leadership |
Whedy Wang | Vp, Head Of Data Science R&d | Leadership |
Yannick Fontes | Head Of Commercial Western Europe & Canada | Leadership |
James Colanero | Director Global QMS | Leadership |
Marc Hefner | Director, Regulatory Informatics | Leadership |
Kaleigh Bulloch Whitehall | Director Scientific Communication | Leadership |
Lorcan Cosgrave | Head Of Commercial Support | Leadership |
Visali Ramanathan | Vp, Business Development | Leadership |
Beatrice Chen | Senior Director, Regional Head Of Finance, Asia Pacific | Leadership |
Tiago Barros | Senior Area Director Portugal & Israel | Leadership |
Jessica Mora | Associate Director, Global Operational Excellence | Leadership |
Yaniris Silva | Country Director Biomarin México | Leadership |
Suresh Kumar Agarwal | Senior Director, Clinical Pharmacology | Leadership |
James Powell | Senior Director, Asset Team Lead, Skeletal Conditions Business Unit | Leadership |
Allyson Nicholson | Vice President Of Global Supply Chain | Leadership |
Nick C. | Sr. Director, Omnichannel Operations | Leadership |
743 more people are available in the full profile.
Complete people profiles for BioMarin Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioMarin Pharmaceutical
BioMarin Pharmaceutical is a publicly listed company on the NASDAQ with ticker symbol BMRN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jan 2018
- Listed onLSE: OHNC
- Listed entityBioMarin Pharmaceutical Inc.
- Exchange sectorHealth technology
- ISINUS09061G1013
- Share price$54.38 (-1.82% on the day) · 2026-10-13
- Market capitalisation$10.53B
- Price to earnings146.6
- EPS (diluted, trailing year)$0.37
- Volume (last session)2,661,697
Financials of BioMarin Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.24B | $348.9M | $971.9M |
| 2024 | $2.84B | $426.9M | $626.2M |
| 2023 | $2.42B | $167.7M | $298.8M |
| 2022 | $2.05B | $141.6M | $110.4M |
| 2021 | $1.85B | -$64.1M | $36.7M |
Detailed financial statements for BioMarin Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioMarin Pharmaceutical
BioMarin Pharmaceutical has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Amicus Therapeutics, Inozyme Pharma and Kuvan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapies for rare and orphan diseases | amicusrx.com | Philadelphia, United States | 2002 | Dec 2025 | •••• | |
Developer of treatments for rare and debilitating metabolic diseases | inozyme.com | Cambridge, United States | 2016 | May 2025 | $270M | |
RNA-modulating therapeutics for neuromuscular disorders were developed. | prosensa.eu | Leiden, Netherlands | 2002 | Nov 2014 | $680M | |
Small molecule therapeutics targeting glycan biosynthesis are developed. | zacharon.com | San Diego, United States | 2004 | Jan 2013 | $10M | |
Enzyme replacement therapies for lysosomal storage diseases | zystor.com | Milwaukee, United States | 2004 | Aug 2010 | $115M | |
Drug discovery company developing therapeutics for cancer and infectious diseases treatment. | leadtherapeutics.com | San Bruno, United States | 2006 | Feb 2010 | •••• | |
Provider of prescription medication for phenylketonuria (PKU) | kuvan.com | 0 | Dec 2007 | •••• |
Complete acquisition details for BioMarin Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioMarin Pharmaceutical
11 dated milestones of BioMarin Pharmaceutical across 28 years, from founding to its latest funding, stage changes and deals.
- Founded BioMarin Pharmaceutical is founded.
- Funding First funding round of $1.5M.
- Acquisition Acquires Kuvan.
- Acquisition Acquires LEAD Therapeutics.
- Acquisition Acquires ZyStor Therapeutics.
- Acquisition Acquires Zacharon Pharmaceuticals.
- Acquisition Acquires Prosensa.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $500.0M.
- Acquisition Acquires Inozyme Pharma.
- Acquisition Acquires Amicus Therapeutics.
Competitors of BioMarin Pharmaceutical
BioMarin Pharmaceutical has 3 listed competitors in our database, 3 of them funded. They include Ultragenyx, Alnylam and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of BioMarin Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioMarin Pharmaceutical
The website of BioMarin Pharmaceutical (biomarin.com) receives about 149.6K visits a month and ranks #316,116 among all websites worldwide, #11,068 in Biotechnology and Pharmaceuticals.
- Monthly visits149.6K
▲ 17.2% vs previous month
- Unique visitors66.8K
per month
- Global rank#316,116
among all websites
- Category rank#11,068
Health · Biotechnology and Pharmaceuticals
- Bounce rate52%
- Pages per visit2.1
- Average visit1 min 29 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with BioMarin Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
jobs.takeda.com | jobs.takeda.com | 100% | #185,912 | – | |
bmrn.com | bmrn.com | 96% | #5,261,449 | – | |
| pharmaphorum.com | 95% | 128.2K | #451,885 | View details | |
pfizer.ie | pfizer.ie | 95% | #1,660,079 | – | |
usa.lutronic.com | usa.lutronic.com | 69% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for BioMarin Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as BioMarin Pharmaceutical (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomarin Pharmaceutical
Complete news archive for BioMarin Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMarin Pharmaceutical
BioMarin Pharmaceutical was founded in 1997.
BioMarin Pharmaceutical is headquartered in San Rafael, United States. It is registered at San Rafael, California, United States.
Jean Jacques Bienaime is the CEO of BioMarin Pharmaceutical, as recorded in our data.
BioMarin Pharmaceutical is a funded company, having raised a total of $37.5M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Feb 1997.
BioMarin Pharmaceutical has 3,040 employees.
Annual revenue of BioMarin Pharmaceutical is $3.24B as on Dec 31, 2025.
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, United States. Therapeutics are developed by the company for rare genetic diseases within the biopharmaceutical sector. Multiple products have been created for conditions including mucopolysaccharidosis syndrome and phenylketonuria. Additional therapies are being advanced for disorders such as Duchenne muscular dystrophy, hemophilia A, and Pompe disease. Operations focus on research and product development for these specialized treatments.
BioMarin Pharmaceutical's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Yes, BioMarin Pharmaceutical is publicly traded on NASDAQ under the ticker symbol BMRN.
BioMarin Pharmaceutical has made 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma, and Kuvan.
The website of BioMarin Pharmaceutical receives about 150 thousand visits a month and ranks #316,116 among all websites worldwide.